Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: A systematic review

Journal of Hepatology

Volumn 53, Issue 2, 2010, Pages 348-356

  Papatheodoridis, George V ^a   Lampertico, Pietro ^b   Manolakopoulos, Spilios ^a   Lok, Anna ^c  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Antivirals; Hepatitis B; Hepatocellular carcinoma; Lamivudine; Nucleoside analogues; Nucleotide analogues

Indexed keywords

ADEFOVIR; EMTRICITABINE; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; NUCLEOTIDE DERIVATIVE; ANTIVIRUS AGENT; CYTOSINE; NUCLEOSIDE;

CANCER INCIDENCE; HEPATITIS B; HIGH RISK PATIENT; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; PRIORITY JOURNAL; REMISSION; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; ADULT; ANALOGS AND DERIVATIVES; CARCINOMA, HEPATOCELLULAR; COMPLICATION; FEMALE; HEPATITIS B, CHRONIC; INCIDENCE; LIVER NEOPLASMS; MALE; MIDDLE AGED;

ADULT; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; CYTOSINE; FEMALE; HEPATITIS B, CHRONIC; HUMANS; INCIDENCE; LAMIVUDINE; LIVER NEOPLASMS; MALE; MIDDLE AGED; NUCLEOSIDES; RISK FACTORS;

EID: 77955306935     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2010.02.035     Document Type: Review

References (42)

1. H.B. El-Serag, and K.L. Rudolph Hepatocellular carcinoma: epidemiology and molecular carcinogenesis Gastroenterology 132 2007 2557 2576
2. D.F. Schafer, and M.F. Sorrell Hepatocellular carcinoma Lancet 353 1999 1253 1257
3. H.B. El-Serag, and A.C. Mason Rising incidence of hepatocellular carcinoma in the United States N Engl J Med 340 1999 745 750
4. K. Okuda Hepatocellular carcinoma J Hepatol 32 2000 225 237
5. A. Maringhini, M. Cottone, E. Sciarrino, M.P. Marceno, F. La Seta, and G. Fusco Ultrasonography and alpha-fetoprotein in diagnosis of hepatocellular carcinoma in cirrhosis Dig Dis Sci 33 1988 47 51
6. M.H. Chang, S.L. You, C.J. Chen, C.J. Liu, C.M. Lee, and S.M. Lin Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study J Natl Cancer Inst 101 2009 1348 1355
7. W.C. Maddrey Hepatitis B: an important public health issue J Med Virol 61 2000 362 366
8. C.J. Chen, H.I. Yang, J. Su, C.L. Jen, S.L. You, and S.N. Lu Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level JAMA 295 2006 65 73
9. A.S.F. Lok, and B.J. McMahon Chronic hepatitis B Hepatology 45 2007 507 539
10. G.V. Papatheodoridis, S. Manolakopoulos, G. Dusheiko, and A.J. Archimandritis Therapeutic strategies in the management of patients with chronic hepatitis B Lancet Infect Dis 8 2008 167 178
11. European Association for the Study of the Liver EASL clinical practice guidelines: management of chronic hepatitis B J Hepatol 50 2009 227 242
12. A. Craxi, D. Di Bona, and C. Camma Interferon-a for HBeAg-positive chronic hepatitis B J Hepatol 39 2003 S99 S105
13. G.V. Papatheodoridis, E. Manesis, and S.J. Hadziyannis The long-term outcome of interferon - a treated and untreated patients with HBeAg-negative chronic hepatitis B J Hepatol 34 2001 306 313
14. P. Lampertico, E. Del Ninno, M. Vigano, R. Romeo, M.F. Donato, and E. Sablon Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy Hepatology 37 2003 756 763 (Pubitemid 36397385)
15. S.M. Lin, M.L. Yu, C.M. Lee, R.N. Chien, I.S. Sheen, and C.M. Chu Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma J Hepatol 46 2007 45 52
16. M.F. Yuen, C.K. Hui, C.C. Cheng, C.H. Wu, Y.P. Lai, and C.L. Lai Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: the effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications Hepatology 34 2001 139 145
17. J.J. Sung, K.K. Tsoi, V.W. Wong, K.C. Li, and H.L. Chan Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma Aliment Pharmacol Ther 28 2008 1067 1077
18. A.S. Lok, C.L. Lai, N. Leung, G.B. Yao, Z.Y. Cui, and E.R. Schiff Long-term safety of lamivudine treatment in patients with chronic hepatitis B Gastroenterology 125 2003 1714 1722
19. P. Andreone, A. Gramenzi, C. Cursaro, M. Biselli, C. Camma, and F. Trevisani High risk of hepatocellular carcinoma in anti-HBe positive liver cirrhosis patients developing lamivudine resistance J Viral Hepat 11 2004 439 442
20. V. Di Marco, A. Marzano, P. Lampertico, P. Andreone, T. Santantonio, and P.L. Almasio Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine Hepatology 40 2004 883 891
21. S. Gaia, A. Marzano, A. Smedile, V. Barbon, M.L. Abate, and A. Olivero Four years of treatment with lamivudine: clinical and virological evaluations in HBe antigen-negative chronic hepatitis B Aliment Pharmacol Ther 20 2004 281 287
22. Y.F. Liaw, J.J. Sung, W.C. Chow, G. Farrell, C.Z. Lee, and H. Yuen Lamivudine for patients with chronic hepatitis B and advanced liver disease N Engl J Med 351 2004 1521 1531
23. R.G. Gish, H. Trinh, N. Leung, F.K. Chan, M.W. Fried, and T.L. Wright Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: a two-year study J Hepatol 43 2005 60 66
24. D.N. Moskovitz, C. Osiowy, E. Giles, G. Tomlinson, and E.J. Heathcote Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance J Viral Hepat 12 2005 398 404
25. N. Akuta, F. Suzuki, Y. Suzuki, H. Sezaki, T. Hosaka, and T. Someya Favorable efficacy of long-term lamivudine therapy in patients with chronic hepatitis B: an 8-year follow-up study J Med Virol 75 2005 491 498
26. G.V. Papatheodoridis, E. Dimou, K. Dimakopoulos, S. Manolakopoulos, I. Rapti, and G. Kitis Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine Hepatology 42 2005 121 129
27. V. Di Marco, R. Di Stefano, D. Ferraro, P.L. Almasio, C. Bonura, and P.M. Giglio HBV-DNA suppression and disease course in HBV cirrhosis patients on long-term lamivudine therapy Antivir Ther 10 2005 431 439
28. S. Manolakopoulos, S. Bethanis, J. Elefsiniotis, S. Karatapanis, C. Triantos, and G. Sourvinos Lamivudine monotherapy in HBeAg-negative chronic hepatitis B: prediction of response-breakthrough and long-term clinical outcome Aliment Pharmacol Ther 23 2006 787 795
29. S.J. Hadziyannis, N.C. Tassopoulos, E.J. Heathcote, T.T. Chang, G. Kitis, and M. Rizzetto Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years Gastroenterology 131 2006 1743 1751
30. I. Rapti, E. Dimou, P. Mitsoula, and S.J. Hadziyannis Adding-on versus switching-to adefovir therapy in lamivudine resistant HBeAg-negative chronic hepatitis B Hepatology 45 2007 307 313
31. M. Buti, I. Elefsiniotis, R. Jardi, V. Vargas, F. Rodriguez-Frias, and M. Schapper Viral genotype and baseline load predict the response to adefovir treatment in lamivudine-resistant chronic hepatitis B patients J Hepatol 47 2007 366 372
32. M.F. Yuen, W.K. Seto, D.H. Chow, K. Tsui, D.K. Wong, and V.W. Ngai Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease Antivir Ther 12 2007 1295 1303
33. P. Lampertico, M. Vigano, E. Manenti, M. Iavarone, E. Sablon, and M. Colombo Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients Gastroenterology 133 2007 1445 1451
34. V.W. Wong, G.L. Wong, S.W. Tsang, A.Y. Hui, A.M. Chim, and K.K. Yiu Long-term follow-up of lamivudine treatment in patients with severe acute exacerbation of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B Antivir Ther 13 2008 571 579
35. Z.M. Kilic, S. Kuran, M. Akdogan, B. Cicek, D. Oguz, and B. Odemis The long-term effects of lamivudine treatment in patients with HBeAg-negative liver cirrhosis Adv Ther 25 2008 190 200
36. T. Nishida, H. Kobashi, S. Fujioka, K. Fujio, K. Takaguchi, and H. Ikeda A prospective and comparative cohort study on efficacy and drug resistance during long-term lamivudine treatment for various stages of chronic hepatitis B and cirrhosis J Gastroenterol Hepatol 23 2008 794 803
37. N. Akuta, F. Suzuki, Y. Kawamura, H. Yatsuji, H. Sezaki, and Y. Suzuki Virological response and hepatocarcinogenesis in lamivudine-resistant hepatitis B virus genotype C patients treated with lamivudine plus adefovir dipivoxil Intervirology 51 2008 385 393
38. R. Idilman, S. Kaymakoglu, O.F. Oguz, E. Ahishali, M. Bektas, and K. Cinar A short course of add-on adefovir dipivoxil treatment in lamivudine-resistant chronic hepatitis B patients J Viral Hepat 16 2009 279 285
39. D.A. Shafritz, D. Shouval, H.I. Sherman, S.J. Hadziyannis, and M.C. Kew Integration of hepatitis B virus DNA into the genome of liver cells in chronic liver disease and hepatocellular carcinoma. Studies in percutaneous liver biopsies and post-mortem tissue specimens N Engl J Med 305 1981 1067 1073
40. P. Laurent-Puig, P. Legoix, O. Bluteau, J. Belghiti, D. Franco, and F. Binot Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis Gastroenterology 120 2001 1763 1773
41. N. Warner, and S. Locarnini The antiviral drug selected hepatitis B virus rtA181T/sW172 mutant has a dominant negative secretion defect and alters the typical profile of viral rebound Hepatology 48 2008 88 98
42. M.W. Lai, and C.T. Yeh The oncogenic potential of hepatitis B virus rtA181T/ surface truncation mutant Antivir Ther 13 2008 875 879